

Currently released so far... 51122 / 251,287
Articles
Brazil
Sri Lanka
United Kingdom
Sweden
00. Editorial
United States
Latin America
Egypt
Jordan
Yemen
Thailand
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
2011/05/01
2011/05/02
2011/05/03
2011/05/04
2011/05/05
2011/05/06
2011/05/07
2011/05/08
2011/05/09
2011/05/10
2011/05/11
2011/05/12
2011/05/13
2011/05/14
2011/05/15
2011/05/16
2011/05/17
2011/05/18
2011/05/19
2011/05/20
2011/05/21
2011/05/22
2011/05/23
2011/05/24
2011/05/25
2011/05/26
2011/05/27
2011/05/28
2011/05/29
2011/05/30
2011/05/31
2011/06/01
2011/06/02
2011/06/03
2011/06/04
2011/06/05
2011/06/06
2011/06/07
2011/06/08
2011/06/09
2011/06/10
2011/06/11
2011/06/12
2011/06/13
2011/06/14
2011/06/15
2011/06/16
2011/06/17
2011/06/18
2011/06/19
2011/06/20
2011/06/21
2011/06/22
2011/06/23
2011/06/24
2011/06/25
2011/06/26
2011/06/27
2011/06/28
2011/06/29
2011/06/30
2011/07/01
2011/07/02
2011/07/04
2011/07/05
2011/07/06
2011/07/07
2011/07/08
2011/07/10
2011/07/11
2011/07/12
2011/07/13
2011/07/14
2011/07/15
2011/07/16
2011/07/17
2011/07/18
2011/07/19
2011/07/20
2011/07/21
2011/07/22
2011/07/23
2011/07/25
2011/07/27
2011/07/28
2011/07/29
2011/07/31
2011/08/01
2011/08/02
2011/08/03
2011/08/05
2011/08/06
2011/08/07
2011/08/08
2011/08/09
2011/08/10
2011/08/11
2011/08/12
2011/08/13
2011/08/15
2011/08/16
2011/08/17
2011/08/18
2011/08/19
2011/08/21
2011/08/22
2011/08/23
2011/08/24
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Antananarivo
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Alexandria
Consulate Adana
American Institute Taiwan, Taipei
Embasy Bonn
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Brazzaville
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangui
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Belfast
Consulate Barcelona
Embassy Cotonou
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chiang Mai
Consulate Chennai
Consulate Chengdu
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
DIR FSINFATC
Consulate Dusseldorf
Consulate Durban
Consulate Dubai
Consulate Dhahran
Embassy Guatemala
Embassy Grenada
Embassy Georgetown
Embassy Gaborone
Consulate Guayaquil
Consulate Guangzhou
Consulate Guadalajara
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Hong Kong
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kolonia
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Krakow
Consulate Kolkata
Consulate Karachi
Embassy Luxembourg
Embassy Lusaka
Embassy Luanda
Embassy London
Embassy Lome
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy Libreville
Embassy La Paz
Consulate Leipzig
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Mission Geneva
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Mogadishu
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maseru
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Merida
Consulate Melbourne
Consulate Matamoros
Consulate Marseille
Embassy Nouakchott
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Nuevo Laredo
Consulate Naples
Consulate Naha
Consulate Nagoya
Embassy Pristina
Embassy Pretoria
Embassy Praia
Embassy Prague
Embassy Port Of Spain
Embassy Port Moresby
Embassy Port Louis
Embassy Port Au Prince
Embassy Podgorica
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Hillah
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Surabaya
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy Tirana
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
Consulate Thessaloniki
USUN New York
USMISSION USTR GENEVA
USEU Brussels
US Office Almaty
US Mission Geneva
US Mission CD Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
UN Rome
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vientiane
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AMGT
ASEC
AEMR
AR
APECO
AU
AORC
ADANA
AJ
AF
AFIN
AMED
AS
AM
ABLD
AFFAIRS
AMB
APER
ACOA
AND
AA
AE
AADP
AID
AO
AL
AG
AORD
ADM
AINF
AINT
ASEAN
AORG
ABT
APEC
AY
ASUP
ARF
AGOA
AVIAN
ATRN
ANET
AGIT
ASECVE
ABUD
AODE
ALOW
ADB
AN
ADPM
ASPA
ARABL
AFSN
AZ
AC
AIAG
AFSI
ASCE
ASIG
ACABQ
ADIP
AFGHANISTAN
AROC
ADCO
ACOTA
ANARCHISTS
AMEDCASCKFLO
AK
ARABBL
ASCH
ANTITERRORISM
AGRICULTURE
AOCR
ARR
ASSEMBLY
AORCYM
AFPK
ACKM
AGMT
AEC
APRC
AIN
AFPREL
ASFC
ASECTH
AFSA
AINR
AOPC
AFAF
AFARI
AX
ASECAF
ASECAFIN
AT
AFZAL
APCS
AGAO
AIT
ARCH
AEMRASECCASCKFLOMARRPRELPINRAMGTJMXL
AMEX
ARM
AQ
ATFN
AMBASSADOR
AORCD
AVIATION
ARAS
AINFCY
ACBAQ
AOPR
AREP
AOIC
ASEX
ASEK
AER
AGR
AMCT
AVERY
APR
AEMRS
AFU
AMG
ATPDEA
ASECKFRDCVISKIRFPHUMSMIGEG
AORL
ACS
AMCHAMS
AECL
AUC
ACAO
BA
BR
BB
BG
BEXP
BY
BRUSSELS
BU
BD
BTIO
BK
BL
BE
BMGT
BO
BM
BX
BN
BWC
BBSR
BTT
BC
BH
BILAT
BUSH
BHUM
BT
BTC
BMENA
BOND
BAIO
BP
BF
BRPA
BURNS
BUT
BBG
BCW
BOEHNER
BOL
BASHAR
BIDEN
BFIN
BZ
BEXPC
BTIU
CPAS
CA
CASC
CS
CBW
CIDA
CO
CODEL
CI
CROS
CU
CH
CWC
CMGT
CVIS
CDG
CTR
CG
CF
CHIEF
CJAN
CBSA
CE
CY
CB
CW
CM
CHR
CD
COE
CV
COUNTER
CT
CN
CPUOS
CTERR
CVR
CVPR
CDC
COUNTRY
CLEARANCE
CONS
COM
CACS
CR
CONTROLS
CAN
CACM
COMMERCE
CAMBODIA
CFIS
COUNTERTERRORISM
CITES
CONDOLEEZZA
CZ
CTBT
CEN
CLINTON
CFED
CARC
CTM
CARICOM
CSW
CICTE
CYPRUS
CBE
CMGMT
CARSON
CWCM
CIVS
COUNTRYCLEARANCE
CENTCOM
CAPC
COPUOS
CKGR
CITEL
CQ
CITT
CIC
CARIB
CVIC
CAFTA
CVISU
CDB
CEDAW
CNC
CJUS
COMMAND
CENTER
COL
CAJC
CONSULAR
CLMT
CBC
CIA
CNARC
CIS
CEUDA
CHINA
CAC
CL
DR
DJ
DEMOCRATIC
DEMARCHE
DOMESTIC
DISENGAGEMENT
DB
DA
DHS
DAO
DCM
DAVID
DO
DEAX
DEFENSE
DEA
DTRO
DPRK
DOC
DTRA
DK
DAC
DOD
DRL
DRC
DCG
DE
DOT
DEPT
DOE
DS
DKEM
ECON
ETTC
EFIS
ETRD
EC
EMIN
EAGR
EAID
EFIN
EUN
ECIN
EG
EWWT
EINV
ENRG
ELAB
EPET
EIND
EN
EAIR
EUMEM
ECPS
ES
EI
ELTN
ET
EZ
EU
ER
EINT
ENGR
ECONOMIC
ENIV
EFTA
ETRN
EMS
EUREM
EPA
ESTH
EEB
EET
ENV
EAG
EXIM
ECTRD
ELNT
ENVIRONMENT
ECA
EAP
EINDIR
ETR
ECONOMY
ETRC
ELECTIONS
EICN
EXPORT
EARG
EGHG
EID
ETRO
EINF
EAIDHO
ECIP
EENV
EURM
EPEC
ERNG
ENERG
EIAD
EXBS
ED
EREL
ELAM
EK
EWT
ENGRD
EDEV
ECE
ENGY
EXIMOPIC
ETRDEC
ECCT
EUR
ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID
EFI
ECOSOC
EXTERNAL
ESCAP
ETCC
EENG
ERA
ENRD
ECLAC
ETRAD
EBRD
ENVR
ECONENRG
ELTNSNAR
ELAP
EPIT
EDUC
EAIDXMXAXBXFFR
EETC
EIVN
EDRC
EGOV
ETRA
EAIDRW
ETRDEINVECINPGOVCS
ESA
ETRDGK
ENVI
ELN
EPRT
EPTED
ERTD
EUM
EAIDS
EFINECONEAIDUNGAGM
EDU
EV
EAIDAF
EDA
EPREL
EINVEFIN
EAGER
ETMIN
EUCOM
ECCP
EIDN
EINVKSCA
ENNP
EFINECONCS
ETC
EAIRASECCASCID
EINN
ETRP
ECONOMICS
ENERGY
EIAR
EINDETRD
ECONEFIN
EURN
ETRDEINVTINTCS
EFIM
ETIO
EATO
EIPR
EINVETC
ETTD
ETDR
EIQ
ECONCS
ENRGIZ
EAIG
ENTG
EUC
ERD
EINVECONSENVCSJA
EEPET
EUNCH
ESENV
ECINECONCS
ETRDECONWTOCS
ECUN
FR
FI
FOREIGN
FARM
FIR
FAO
FK
FARC
FAS
FJ
FREEDOM
FAC
FINANCE
FBI
FTAA
FM
FCS
FAA
FORCE
FDA
FTA
FT
FCSC
FMGT
FINR
FIN
FDIC
FOR
FOI
FO
FMLN
FISO
GM
GERARD
GT
GA
GG
GR
GTIP
GH
GZ
GE
GB
GY
GAZA
GJ
GEORGE
GOI
GCC
GMUS
GI
GLOBAL
GV
GC
GL
GOV
GKGIC
GF
GWI
GIPNC
GUTIERREZ
GTMO
GANGS
GAERC
GUILLERMO
GASPAR
HR
HA
HYMPSK
HO
HK
HUMAN
HU
HN
HHS
HURI
HUD
HUMRIT
HUMANITARIAN
HUMANR
HL
HSTC
HILLARY
HCOPIL
HADLEY
HOURANI
HI
HUM
HEBRON
HUMOR
IZ
IN
IAEA
IS
IMO
ILO
IR
IC
IT
ITU
ID
IV
IMF
IBRD
IWC
ICAO
ICRC
INF
IO
IPR
ISO
IK
ISRAELI
IQ
ICES
IDB
INFLUENZA
IRAQI
ISCON
IGAD
IRAN
ITALY
IRAQ
ICTY
ICTR
ITPGOV
ITALIAN
IQNV
IADB
INTERNAL
INMARSAT
IRDB
ILC
INCB
INRB
ICJ
ISRAEL
INR
IEA
ISPA
ICCAT
IOM
ITRD
IHO
IL
IFAD
ITRA
IDLI
ISCA
INL
INRA
INTELSAT
ISAF
ISPL
IRS
IEF
ITER
INDO
IIP
IND
IEFIN
IACI
IAHRC
INNP
IA
INTERPOL
IFIN
ISSUES
IZPREL
IRAJ
IF
ITPHUM
ITA
IP
IRPE
IDA
ISLAMISTS
ITF
INRO
IBET
IDP
IRC
KMDR
KPAO
KOMC
KNNP
KFLO
KDEM
KSUM
KIPR
KFLU
KE
KCRM
KJUS
KAWC
KZ
KSCA
KDRG
KCOR
KGHG
KPAL
KTIP
KMCA
KCRS
KPKO
KOLY
KRVC
KVPR
KG
KWBG
KTER
KS
KN
KSPR
KWMN
KV
KTFN
KFRD
KU
KSTC
KSTH
KISL
KGIC
KSEP
KFIN
KTEX
KTIA
KUNR
KCMR
KCIP
KMOC
KTDB
KBIO
KBCT
KMPI
KSAF
KACT
KFEM
KPRV
KPWR
KIRC
KCFE
KRIM
KHIV
KHLS
KVIR
KNNNP
KCEM
KLIG
KIRF
KNUP
KSAC
KNUC
KPGOV
KTDD
KIDE
KOMS
KLFU
KNNC
KMFO
KSEO
KJRE
KJUST
KMRS
KSRE
KGIT
KPIR
KPOA
KUWAIT
KIVP
KICC
KSCS
KPOL
KSEAO
KRCM
KSCI
KNAP
KGLB
KICA
KCUL
KPRM
KFSC
KQ
KPOP
KPFO
KPALAOIS
KREC
KBWG
KR
KTTB
KNAR
KCOM
KESS
KINR
KOCI
KWN
KCSY
KREL
KTBT
KFTN
KW
KRFD
KFLOA
KHDP
KNEP
KIND
KHUM
KSKN
KOMO
KDRL
KTFIN
KSOC
KPO
KGIV
KSTCPL
KSI
KPRP
KFPC
KNNB
KNDP
KICCPUR
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KDMR
KFCE
KIMMITT
KMCC
KMNP
KSEC
KOMCSG
KGCC
KRAD
KCRP
KAUST
KWAWC
KCHG
KRDP
KPAS
KTIAPARM
KPAOPREL
KWGB
KIRP
KMIG
KLAB
KSEI
KHSA
KNPP
KPAONZ
KWWW
KGHA
KY
KCRIM
KCRCM
KGCN
KPLS
KIIP
KPAOY
KTRD
KTAO
KJU
KBTS
KWAC
KFIU
KNNO
KPAI
KILS
KPA
KRCS
KWBGSY
KNPPIS
KNNPMNUC
KNPT
KERG
KLTN
KPREL
KTLA
KO
KAWK
KVRP
KAID
KX
KENV
KWCI
KNPR
KCFC
KNEI
KFTFN
KTFM
KCERS
KDEMAF
KMEPI
KEMS
KBTR
KEDU
KIRL
KNNR
KMPT
KPDD
KPIN
KDEV
KFRP
KTBD
KMSG
KWWMN
KWBC
KA
KOM
KWNM
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KRGY
KNNF
KICR
KIFR
KWMNCS
KPAK
KDDG
KCGC
KID
KNSD
KMPF
KWMM
MARR
MX
MASS
MOPS
MNUC
MCAP
MTCRE
MRCRE
MTRE
MASC
MY
MK
MG
MU
MILI
MO
MZ
MEPP
MCC
MEDIA
MOPPS
MI
MAS
MW
MP
MEPN
MV
MD
MR
MC
MCA
MT
MIL
MARITIME
MOPSGRPARM
MAAR
MOOPS
ML
MA
MN
MNUCPTEREZ
MTCR
MUNC
MPOS
MONUC
MGMT
MURRAY
MACP
MINUSTAH
MCCONNELL
MGT
MNUR
MF
MEPI
MOHAMMAD
MAR
MAPP
MNU
MFA
MTS
MLS
MEETINGS
MERCOSUR
MED
MNVC
MIK
MBM
MILITARY
MAPS
MARAD
MDC
MACEDONIA
MASSMNUC
MUCN
MQADHAFI
MPS
NZ
NATO
NI
NO
NU
NG
NL
NPT
NS
NA
NP
NASA
NSF
NEA
NANCY
NSG
NRR
NATIONAL
NMNUC
NC
NSC
NAS
NARC
NELSON
NATEU
NDP
NIH
NK
NIPP
NR
NERG
NSSP
NE
NTDB
NT
NEGROPONTE
NGO
NATOIRAQ
NAR
NZUS
NCCC
NH
NAFTA
NEW
NRG
NUIN
NOVO
NATOPREL
NV
NICHOLAS
NPA
NSFO
NW
NORAD
NPG
NOAA
OPRC
OPDC
OTRA
OECD
OVIP
OREP
ODC
OIIP
OAS
OSCE
OPIC
OMS
OFDP
OFDA
OEXC
OPCW
OIE
OSCI
OM
OPAD
ODPC
OIC
ODIP
OPPI
ORA
OCEA
OREG
OMIG
OFFICIALS
OSAC
OEXP
OPEC
OFPD
OAU
OCII
OIL
OVIPPRELUNGANU
OSHA
OPCD
OPCR
OF
OFDPQIS
OSIC
OHUM
OTR
OBSP
OGAC
OESC
OVP
ON
OES
OTAR
OCS
PREL
PGOV
PARM
PINR
PHUM
PM
PREF
PTER
PK
PINS
PBIO
PHSA
PE
PBTS
PA
PL
POL
PAK
POV
POLITICS
POLICY
PO
PRELTBIOBA
PKO
PIN
PNAT
PU
PGOVPREL
PALESTINIAN
PTERPGOV
PELOSI
PAS
PP
PTEL
PROP
PRELAF
PRHUM
PRE
PUNE
PIRF
PVOV
PROG
PERSONS
PROV
PKK
PRGOV
PH
PLAB
PDEM
PCI
PRL
PRM
PINSO
PERM
PETR
PPAO
PERL
PBS
PETERS
PRELBR
PCON
POLITICAL
PMIL
POLM
PKPA
PNUM
PLO
PTERM
PJUS
PARMP
PNIR
PHUMKPAL
PG
PREZ
PGIC
PAO
PROTECTION
PRELPK
PGOVENRG
PATTY
PSOC
PARTIES
PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ
PMIG
PAIGH
PARK
PETER
PHUS
PKPO
PGOVECON
POUS
PMAR
PWBG
PAR
PGOVGM
PHUH
PTE
PY
POLUN
PDOV
PGOVSOCI
PGOVPM
PRELEVU
PGOR
PBTSRU
PHUMA
PHUMR
PPD
PGV
PRAM
PARMS
PINL
PSI
PKPAL
PPA
PTERE
PGOF
PINO
PREO
PHAS
PAC
PRESL
PORG
PS
PGVO
PKFK
PSOE
PEPR
PINT
PRELP
PREFA
PNG
PTBS
PFOR
PGOVLO
PHUMBA
PREK
PHJM
POLINT
PGOVE
PHALANAGE
PARTY
PECON
PEACE
PROCESS
PLN
PEDRO
PF
PGPV
PCUL
PGGV
PSA
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PGIV
PHUMPREL
POGOV
PEL
PBT
PAMQ
PINF
PSEPC
POSTS
PAHO
PHUMPGOV
PGOC
PNR
RS
RP
RU
RW
RFE
RCMP
RIGHTSPOLMIL
REFORM
RO
ROW
ROBERT
REACTION
REPORT
REGION
RELATIONS
RAY
ROBERTG
RIGHTS
RM
RATIFICATION
RREL
RBI
RICE
ROOD
REL
RODHAM
RGY
RUEHZO
RELIGIOUS
RELFREE
RUEUN
RELAM
RSP
RF
REO
REGIONAL
RUPREL
RI
REMON
RPEL
RSO
SCUL
SENV
SOCI
SZ
SNAR
SO
SP
SU
SY
SI
SMIG
SYR
SA
SW
SF
SR
SYRIA
SNARM
START
SPECIALIST
SG
SNIG
SCI
SGWI
SE
SIPDIS
SANC
SELAB
SN
SETTLEMENTS
SCIENCE
SENVENV
SENS
SPCE
SPAS
SECURITY
SENC
SOCIETY
SOSI
SENVEAGREAIDTBIOECONSOCIXR
SEN
SPECI
ST
SL
SENVCASCEAIDID
SC
SECRETARY
STR
SNA
SOCIS
SADC
SEP
SK
SHUM
SYAI
SMIL
STEPHEN
SNRV
SKCA
SENSITIVE
SECI
SCUD
SCRM
SGNV
SECTOR
SAARC
SENVSXE
SWMN
STEINBERG
SOPN
SOCR
SCRS
SWE
SARS
SNARIZ
SUDAN
SENVQGR
SAN
SM
SFNV
SSA
SPCVIS
SOFA
SCULKPAOECONTU
SENVKGHG
SHI
SEVN
SH
SNARCS
SNARN
SIPRS
TBIO
TW
TRGY
TSPA
TU
TPHY
TI
TX
TH
TIP
TSPL
TNGD
TZ
TS
TC
TK
TURKEY
TERRORISM
TPSL
TINT
TRSY
TERFIN
TPP
TT
TECHNOLOGY
TE
TAGS
TRAFFICKING
TJ
TN
TO
TD
TP
TREATY
TR
TA
TIO
TECH
TF
TRAD
TNDG
TWI
TPSA
TWL
TAUSCHER
TRBY
TL
TV
THPY
TSPAM
TREL
TRT
TNAR
TFIN
TWCH
THOMMA
THOMAS
TERROR
TRY
TBID
UK
UNESCO
UNSC
UNGA
UN
US
UZ
USEU
UG
UP
UNAUS
UNMIK
USTR
UY
USUN
UNEP
UNDC
UV
UNPUOS
UNSCR
USAID
UNODC
UNRCR
UNHCR
UNDP
UNCRIME
UA
UNHRC
UNRWA
UNO
UNCND
UNCHR
USAU
UNICEF
USPS
UNOMIG
UNESCOSCULPRELPHUMKPALCUIRXFVEKV
UR
UNFICYP
UNCITRAL
UNAMA
UNVIE
USTDA
USNC
UNCSD
USCC
UNEF
UNGAPL
USSC
UNMIC
UNTAC
UNCLASSIFIED
USDA
UNCTAD
USGS
UNFPA
UNSE
USOAS
UE
UAE
UNCHS
UNDESCO
UNC
UNSCS
UKXG
UNGACG
UNHR
UNBRO
UNCHC
UNFCYP
UNIDROIT
WHTI
WIPO
WTRO
WHO
WTO
WMO
WFP
WEET
WS
WE
WA
WHA
WBG
WILLIAM
WI
WSIS
WCL
WEBZ
WZ
WW
WWBG
WMD
WWT
WMN
WWARD
WITH
WTRQ
WCO
WEU
WB
WBEG
Browse by classification
Community resources
courage is contagious
Viewing cable 04WELLINGTON1037, NEW ZEALAND'S PHARMACEUTICAL MARKET: NO QUICK FIX
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #04WELLINGTON1037.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
04WELLINGTON1037 | 2004-12-15 01:08 | 2011-04-28 00:00 | CONFIDENTIAL | Embassy Wellington |
This record is a partial extract of the original cable. The full text of the original cable is not available.
C O N F I D E N T I A L SECTION 01 OF 04 WELLINGTON 001037
SIPDIS
DEPARTMENT FOR EAP/ANP-TRAMSEY AND EB/TPP/BTA/ANA-RARMSTRONG
STATE PASS TO USTR FOR BWEISEL AND DKATZ
COMMERCE FOR 4530/ITA/MAC/AP/OSAO/GPAINE
E.O. 12958: DECL: 12/14/2014
TAGS: ETRD ECON KIPR NZ
SUBJECT: NEW ZEALAND'S PHARMACEUTICAL MARKET: NO QUICK FIX
REF: A. WELLINGTON 900
¶B. AUCKLAND 302
¶C. AUCKLAND 118
Classified by: DCM David R. Burnett. Reasons: 1.4 (b) and
(d).
¶1. (SBU) Summary: After trying in vain for years to persuade
the New Zealand government to change its restrictive pricing
policies on pharmaceuticals, the drug industry is taking
another tack: reaching out to patient groups with information
designed to bolster their demands for cutting-edge drugs not
already covered by government subsidy. Several U.S. drug
companies also hold out hope that a New Zealand-U.S.
free-trade agreement could be a lever for improving their
access to New Zealand's pharmaceutical market.
¶2. (C) The government contends it already is increasing drug
availability by boosting the budget for pharmaceutical
purchases over the next three years. In actuality, its
spending on drugs in real terms is declining. U.S.
pharmaceutical companies continue to struggle in what they
view as one of the most restricted free-world markets. They
are cutting local staff, and they are slashing investment in
New Zealand-based research and development. Attempting to
make inroads against a government mindset that is hostile to
the drug industry, post is working with the industry to
identify speakers and engage in other public diplomacy
efforts that could help educate New Zealanders on the
benefits of gaining access to a wider range of effective
pharmaceuticals. End summary.
Limited prices, limited access
==============================
¶3. (U) Spending in New Zealand on government-subsidized
pharmaceuticals has risen by less than three percent per year
on average during the last decade, compared to 14 percent per
year in Australia. Only six new drugs a year were approved
on average over the last three years for reimbursement in New
Zealand, compared to about 30 drugs in Australia. The New
Zealand government nevertheless asserts that it now is
increasing the budget for pharmaceuticals sufficiently to
subsidize more new medicines.
¶4. (U) In fact, the pharmaceutical budget rose this fiscal
year (ending June 30) by 4.4 percent, to NZ $541 million (US
$380 million), with planned increases in the following two
years of .5 percent and 1.9 percent. The smaller increases
in the 2006-2007 and 2007-2008 budget years were based on the
expectation that a number of expensive drugs will go off
patent, according to Stuart Bruce, manager of communications
and external relations for the Pharmaceutical Management
Agency (Pharmac), a stand-alone Crown entity.
¶5. (U) Exempt from New Zealand's competition law, Pharmac
acts as a single buyer, or monopsony, that decides which
medicines will be subsidized by the government and how much
reimbursement will be paid for each pharmaceutical. In some
cases, the supplier is not allowed to set a drug price higher
than the subsidy as determined by Pharmac. The agency also
puts a cap on the amount of a drug to be purchased at a
certain price. Its decisions effectively allocate about 73
percent of New Zealand's spending on prescription drugs.
Pharmac does not directly handle funding for the government's
drug subsidy. Those funds are dispersed by the national
health care systems' 21 district health boards to the
pharmaceutical suppliers after a prescribed drug is dispensed
to the consumer.
¶6. (SBU) Bruce noted that Pharmac always under-spends its
budget because government policy prohibits exceeding it.
That means that actual public spending on pharmaceuticals is
likely to remain relatively flat or even decline in real
terms over the next three years. Further explaining why
Pharmac spends less than planned, Bruce said that some
patients do not pick up their prescriptions because of
co-payment delays. Spending projections also are based on
the assumption that patients will consume their entire
prescription. Since pharmacists receive a fee each time they
dispense a medication, they usually break a prescription into
installments, and some patients do not purchase an entire
prescription.
¶7. (C) Pharmac designated 15 new products for reimbursement
the past fiscal year, up from three new drugs in 2002-2003.
U.S. pharmaceutical firms we talked to, however, point out
that only one of those new medicines is freely available.
Access to the other medicines is available only after doctors
make special application or when patients meet specific
criteria. For example, only specialists can prescribe a new
treatment for diabetes. The drug's manufacturer believes
2,000 to 3,000 of the more than 100,000 diabetics in New
Zealand could benefit from the medicine. But with just 50
specialists nationwide, most patients are under the care of
general practitioners, and obtaining the drug is difficult.
Another company reported that six out of 10 applications by
doctors for reimbursement for its schizophrenia drug are
rejected.
¶8. (C) The industry also criticizes Pharmac for a lack of
transparency in its funding decisions. One U.S. company
spent more than three years negotiating with Pharmac to gain
public funding for a schizophrenia treatment. Without
explanation (none is required), Pharmac broke off those
discussions this year.
¶9. (U) The New Zealand industry group Researched Medicines
Industry (RMI) said in a statement that Pharmac is using
"smoke and mirrors" to portray itself as widening New
Zealanders' access to pharmaceuticals. Since leading-edge
medicines generally are not subsidized, they are available
only to those who can pay the full cost, RMI said.
¶10. (SBU) Publicly, Pharmac contends that it delivers the
best health-care outcomes possible within the funding
available, citing the fact that the volume of subsidized
pharmaceuticals has increased while prices in general have
declined. Pharmac highlights the savings it reaps -- NZ $25
million (US $17.5 million) the past fiscal year -- that would
have been spent on the drug subsidy without its intervention
to lower prices. Privately, Wayne McNee, Pharmac's chief
executive officer, acknowledged that the principal obstacle
to funding more medicines is the government's reluctance to
increase the pharmaceutical budget. On that, both he and the
industry agree.
IPR and advertising under threat
================================
¶11. (U) U.S. pharmaceutical companies consider New Zealand's
patent protection to be inadequate. Pharmac controls
pharmaceutical prices partly through "reference pricing" --
determining the level of subsidy based on the lowest-priced
product in a therapeutic subgroup. The subgroup includes
medicines that are similarly effective in treating the same
or similar conditions. This policy often pits patented
products against lower-priced generics and does not reward
innovation. Pharmac's general practice is to designate for
subsidy only one drug per therapeutic class.
¶12. (U) The New Zealand government also has refused to extend
the effective patent life of drugs, which now stands at seven
years on average (ref A). One U.S. company views the issue
as irrelevant, since Pharmac's reference pricing undermines
its patents' commercial value anyway. Most companies see the
government's position on effective patent life as further
evidence of its disregard for the pharmaceutical industry.
Further eroding their patents' worth is the so-called
springboarding provision in New Zealand's patent law, which
allows generic competitors to start the process of seeking
market approval while a proprietary drug is still under
patent.
¶13. (C) In addition, U.S. pharmaceutical companies continue
to worry that the government will ban direct-to-consumer
advertising, one of the industry's few pathways around
Pharmac's controls (ref C). Several companies, especially
those marketing so-called lifestyle drugs for such conditions
as hair loss and erectile dysfunction, have built sales
through advertising. Unsubsidized drugs accounted for 30
percent of sales for Merck Sharp & Dohme, 25 percent for
Pfizer, 20 to 25 percent for Pfizer, 20 percent for Johnson &
Johnson, 15 percent for Eli Lilly and less than 6 percent for
GlaxoSmithKline this year in New Zealand. Health Minister
Annette King and Pharmac oppose direct-to-consumer
advertising (DTCA) partly because they believe it tends to
increase expenditures on pharmaceuticals. DTCA also
pressures Pharmac to explain why it does not fund certain
advertised drugs. Companies are wary of the New Zealand
government using a joint regulatory agency it is establishing
with Australia as a vehicle for banning DTCA, which is not
allowed in Australia. However, the Australian High
Commission told post that such a decision is for the New
Zealand government alone to make.
A big hit on industry
=====================
¶14. (U) From Pharmac's pricing policies to the government's
positions on intellectual property and direct-to-consumer
advertising, U.S. pharmaceutical companies consider New
Zealand to be hostile ground. Unable to meet their sales and
profit targets, they say it is becoming increasingly
difficult to persuade their home offices to keep investments
or even a presence in the country.
¶15. (C) As a result, almost all U.S. companies in New Zealand
have scaled back their staffs and their
research-and-development investments since Pharmac was formed
in 1993. During the past year, Eli Lilly cut 20 percent of
its staff to 27 people, from a peak of 70 employees in the
mid-1990s. GlaxoSmithKline has reduced its staff by 65
percent, down to about 50 people. Pfizer downsized its
pharmaceutical division by 15 percent, to 60 people. Johnson
& Johnson two years ago cut its staff by 10 percent, and Jan
Trotman, its general manager in New Zealand, said that if
conditions do not improve in 2005, the company could leave
the country in three to five years. (Some staff cuts are due
to the shifting of regulatory oversight from New Zealand to
Australia with the scheduled launch of the trans-Tasman
agency in July 2005.) The exception is Merck, where
employment has remained stable and sales have increased,
partly because of its higher sales of vaccines.
¶16. (C) Because of the difficult environment, all the
companies have reduced -- and, in some cases, ceased --
investment in research and development in New Zealand (ref
B). Eli Lilly is completing two clinical trials, but
otherwise has transferred all its research and development.
Ten years ago, every U.S. drug company in New Zealand
employed a medical director. Now, only Merck has one.
Ironically, New Zealand presents a small but optimal
environment for clinical trials of pharmaceuticals because of
its population's lack of exposure to newer medicines.
Minister King had threatened to end clinical trials unless
patients participating in a trial had free, lifetime access
to the medicine once the trial ended. Other cabinet
ministers told her to stop making that threat.
¶17. (SBU) Nearly every company said it was holding out some
of its newer medicines from New Zealand because of the
expectation that prices and sales volumes would be too low.
For the New Zealand consumer, the result is less access to
modern medicines.
Times they are a-changin'?
==========================
¶18. (SBU) Pharmaceutical companies see ideological opposition
to their industry in comments by Prime Minister Clark, Health
Minister King and other cabinet members. One pharmaceutical
executive recalled how, upon simply introducing himself at a
public forum, the Prime Minister said the drug industry
needed to be "stopped" from making excessive profits. (The
industry may be paying a price for its unsuccessful effort in
1990 to unseat Clark, who at the time was health minister.)
Health Minister King has publicly equated the pharmaceutical
industry with the tobacco industry. When several companies
warned her that her government's policies would force the
industry out of New Zealand, she responded that she was not
concerned because New Zealand could always shop overseas for
its drugs.
¶19. (SBU) Amid such perceived hostility, there have been
subtle changes. In the past couple years, RMI and Pharmac
have worked to maintain dialogue, although RMI in recent
months under a new chairman -- a general practitioner -- has
more aggressively promoted the industry's views in the media.
While drug companies remain unhappy with Pharmac's
practices, they see capped government funding, rather than
Pharmac itself, as their primary problem. Several companies
noted an emerging public debate over access to medicines, a
discussion that was nonexistent even a couple years ago.
Public attitudes are changing slowly. As Alister Brown,
Merck New Zealand's chief executive, noted, consumers five
years ago assumed that if Pharmac did not fund a drug, it was
not worth having. An increasing number of consumers are now
willing to pay for non-subsidized drugs.
¶20. (C) Finding that its direct pressure failed to alter the
government mindset, the industry is now firing up pressure
from below. For the last six months, RMI has been working
with patient groups to make them aware of cutting-edge
pharmaceuticals that are not being subsidized in New Zealand.
Lesley Clarke, RMI's chief executive officer, hopes this
effort will result in increased pressure on the government to
hike funding for drugs. Although Clarke said it would be too
early to see results of RMI's efforts, New Zealand newspapers
in recent months have reported complaints by patient groups
over the lack of funding for drugs to treat breast cancer,
Alzheimer's disease, and growth hormone problems.
¶21. (SBU) New Zealand's doctors would appear to be likely
cheerleaders for greater access to pharmaceuticals. However,
industry market research shows that fewer than 20 percent of
New Zealand's doctors would tell their patients of non-funded
alternatives to subsidized medications. The drug companies
contend that doctors are reluctant to publicly call for
change.
¶22. (C) A possible U.S.-New Zealand free-trade agreement
(FTA) offers one last avenue for changing government policies
that limit access to pharmaceuticals, several U.S. companies
said. Meanwhile, Geoff Dangerfield, chief executive of the
New Zealand Ministry of Economic Development, told a U.S.
drug company that his government terminated its study of
patent term extension for pharmaceuticals to keep the issue
as a bargaining chip in the event of FTA negotiations. If
FTA talks go forward, most of the drug companies will be
looking to the U.S. government to win serious concessions
from New Zealand on pharmaceutical issues. Pfizer, which
withdrew from RMI early this year, will oppose free-trade
negotiations until the New Zealand government alters some of
its policies, especially its patent law and reference pricing.
Post's strategy
===============
¶23. (SBU) The challenge is compounded by New Zealand's
escalating health-care costs and an aging population.
Overall health-care spending has risen faster than any
government budget category since 1994 and now comprises about
20 percent of the government budget. In the meantime, the
government's effort to reduce the cost of seeing a doctor has
led to more patient visits, more prescriptions, and more
purchased pharmaceuticals. As a result, Bruce of Pharmac
said his agency would face more pressure to ration its budget
or seek a larger portion of the already stressed health
budget.
¶24. (C) To complement the industry's efforts, post will work
with companies to identify U.S. speakers to be brought to New
Zealand and possible International Visitor Program
participants, with the goal of educating New Zealand's health
practitioners, policymakers and consumers on pharmaceuticals'
role in health care. These programs will emphasize the
advantages of expanded access to medicines and treatment
options and the link between pharmaceutical research and
development and the biotechnology industry, which the New
Zealand government prominently supports as a means to
economic growth. By keeping drug expenses artificially low,
the New Zealand government is denying consumers access to
many modern medicines and failing to bear an equitable
portion of the cost of developing drugs. Over the long term,
post hopes its efforts will help New Zealand strike a balance
between providing affordable medicines and supporting an
industry that creates cures for disease.
Swindells